Welcome to our dedicated page for Scynexis SEC filings (Ticker: SCYX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
SCYNEXIS, Inc.’s SEC filings document a biotechnology company with clinical-stage development programs in rare kidney disease and antifungal medicine. Its reports and current-event filings cover the acquired PXL-770, now SCY-770, AMPK activator assets for ADPKD; SCY-247 clinical and regulatory disclosures; and license arrangements involving ibrexafungerp and BREXAFEMME® with GSK.
SCYNEXIS filings also describe common-stock capitalization, material agreements, risk factors, operating and financial results, and Nasdaq-listed common stock. Proxy materials and Form 8-K reports cover shareholder voting matters, governance, board composition, executive compensation, auditor ratification, and proposed certificate-amendment matters affecting the company’s equity structure.
SCYNEXIS, Inc. is calling a virtual special stockholder meeting on May 19, 2026 to seek approval for a reverse stock split of its common stock at a ratio between 1‑for‑5 and 1‑for‑10, along with a proportional reduction in authorized shares. The board states this flexibility is intended to help the company regain compliance with The Nasdaq Capital Market’s minimum bid price requirement before June 15, 2026 and avoid potential delisting proceedings. As of April 20, 2026, the company had 79,442,633 common shares outstanding and 150,000,000 authorized, which would all be reduced proportionately if the split is implemented.
SCYNEXIS, Inc. is soliciting proxies for its 2026 virtual Annual Meeting of Stockholders to be held on June 25, 2026. The Board asks shareholders to elect six directors, ratify Deloitte & Touche LLP as auditor, approve advisory votes on executive compensation and frequency, approve an increase to the 2024 Equity Incentive Plan share reserve, and approve an amendment to increase authorized common stock to either 60,000,000 (with a reverse split condition) or 300,000,000.
The record date was April 27, 2026. The Board recommends voting FOR all proposals, including a proposed 9,600,000-share increase to the 2024 Plan reserve and the plan amendment that results in a 21,410,683 share maximum under the amended plan. Proxy materials and voting instructions are available online.
SCYNEXIS, Inc. reported that board member Steven C. Gilman plans to retire from the Board and will not stand for reelection at the company’s 2026 annual meeting of stockholders. His term will end at that meeting, when his current directorship expires.
Until the 2026 annual meeting, Dr. Gilman will continue to serve as Chair of the Compensation Committee and as a member of the Nominating and Corporate Governance Committee. The company stated that his decision was not due to any disagreement regarding its operations, policies, practices, strategy, management, or Board.
SCYNEXIS, Inc. is asking shareholders at a virtual Special Meeting on May 19, 2026 to approve an amendment to its certificate of incorporation to permit a reverse stock split of its common stock at a ratio the Board may choose in the range 1-for-5 through 1-for-10. The Board would have discretion whether and when to implement the approved split and to abandon it despite shareholder approval.
The company states the board seeks flexibility to regain or maintain Nasdaq listing compliance and to reduce outstanding share counts; authorized common shares and outstanding shares would be reduced proportionately if the Board effects the split. The record date for voting is April 20, 2026, and proxy materials are available at www.proxyvote.com.
SCYNEXIS INC reports a passive ownership filing showing 7,608,695 shares (9.6% of the class) held by Squadron Master Fund LP and related reporting persons as of 03/31/2026. The statement lists shared voting and dispositive power for the reported holders and cites 79,442,633 shares outstanding as the basis for the percentage calculation.
Great Point Partners, Dr. Jeffrey R. Jay and Ms. Lillian Nordahl report joint beneficial ownership of 7,978,713 shares of SCYNEXIS common stock, representing 9.99% of the class as of 03/31/2026. The filing bases the percentage on a total of 79,866,999 shares outstanding, which includes 424,366 shares issuable upon exercise of warrants held by the reporting persons limited by a Beneficial Ownership Cap. The reporting persons hold 7,554,347 shares outright and hold warrants comprising 8,750,000 pre-funded warrants and 16,304,347 common warrants, subject to exercise limits. The statement also discloses related record holdings: 4,985,869 shares held by Biomedical Value Fund, L.P. and 2,568,478 shares held by Biomedical Offshore Value Fund, Ltd.
SCYNEXIS INC Chief Executive Officer David Angulo Gonzalez purchased additional equity through a private placement. On March 30, 2026, he agreed to buy 108,695 shares of common stock and accompanying warrants to purchase up to 108,695 shares, which closed on April 1, 2026, at a combined purchase price of $0.92 per share and warrant unit. The new Common Warrants will become exercisable once stockholders approve an increase in authorized common shares and will expire on the earlier of five years from issuance or 30 days after SCYNEXIS releases Week 48 topline data from its Phase 2 proof-of-concept clinical study of SCY-770 in autosomal dominant polycystic kidney disease. Following these transactions, he directly owns 1,357,126 shares of common stock, including 4,000 acquired under the 2014 Employee Stock Purchase Plan.
SCYNEXIS, Inc. outlines a new rare-disease strategy built around SCY-770, a Phase 2–ready oral AMP-activated protein kinase activator for autosomal dominant polycystic kidney disease (ADPKD). The company acquired global rights to SCY-770 from Poxel with $8M upfront, up to $8M in development milestones, and up to $180M in commercial milestones, with no royalties.
SCYNEXIS reports a stronger balance sheet, highlighting approximately $56M in cash, cash equivalents and investments as of December 31, 2025 and about $40M of gross proceeds from a recent PIPE financing, extending its cash runway into mid-2029. Management plans to start a Phase 2 proof-of-concept study in ADPKD in Q4 2026, targeting an early efficacy readout in the second half of 2027, while continuing to advance antifungal candidate SCY-247 and royalty-bearing asset BREXAFEMME.
SCYNEXIS, Inc. outlines a new rare-disease strategy built around SCY-770, a Phase 2–ready oral AMP-activated protein kinase activator for autosomal dominant polycystic kidney disease (ADPKD). The company acquired global rights to SCY-770 from Poxel with $8M upfront, up to $8M in development milestones, and up to $180M in commercial milestones, with no royalties.
SCYNEXIS reports a stronger balance sheet, highlighting approximately $56M in cash, cash equivalents and investments as of December 31, 2025 and about $40M of gross proceeds from a recent PIPE financing, extending its cash runway into mid-2029. Management plans to start a Phase 2 proof-of-concept study in ADPKD in Q4 2026, targeting an early efficacy readout in the second half of 2027, while continuing to advance antifungal candidate SCY-247 and royalty-bearing asset BREXAFEMME.
SCYNEXIS, Inc. outlines a new rare-disease strategy built around SCY-770, a Phase 2–ready oral AMP-activated protein kinase activator for autosomal dominant polycystic kidney disease (ADPKD). The company acquired global rights to SCY-770 from Poxel with $8M upfront, up to $8M in development milestones, and up to $180M in commercial milestones, with no royalties.
SCYNEXIS reports a stronger balance sheet, highlighting approximately $56M in cash, cash equivalents and investments as of December 31, 2025 and about $40M of gross proceeds from a recent PIPE financing, extending its cash runway into mid-2029. Management plans to start a Phase 2 proof-of-concept study in ADPKD in Q4 2026, targeting an early efficacy readout in the second half of 2027, while continuing to advance antifungal candidate SCY-247 and royalty-bearing asset BREXAFEMME.
SCYNEXIS, Inc. entered into a private placement with institutional and accredited investors to raise approximately $40.0 million in gross proceeds. The company will issue 34,750,000 common shares, 8,750,000 pre-funded warrants, and accompanying common warrants to purchase up to 43,500,000 shares or pre-funded warrants.
Common shares plus warrants are priced at $0.92 per unit, and pre-funded warrant units at $0.9199. Common warrants carry a $1.20 exercise price and become exercisable after stockholder approval of an authorized share increase. If all warrants are exercised for cash, SCYNEXIS could receive up to an additional $52.2 million.
The company plans to use net proceeds for working capital and general corporate purposes. It estimates that existing cash, cash equivalents and marketable securities, together with anticipated net proceeds from this financing, will fund operations into mid‑2029, supporting development of programs including SCY‑770 for autosomal dominant polycystic kidney disease.
SCYNEXIS, Inc. entered into a private placement with institutional and accredited investors to raise approximately $40.0 million in gross proceeds. The company will issue 34,750,000 common shares, 8,750,000 pre-funded warrants, and accompanying common warrants to purchase up to 43,500,000 shares or pre-funded warrants.
Common shares plus warrants are priced at $0.92 per unit, and pre-funded warrant units at $0.9199. Common warrants carry a $1.20 exercise price and become exercisable after stockholder approval of an authorized share increase. If all warrants are exercised for cash, SCYNEXIS could receive up to an additional $52.2 million.
The company plans to use net proceeds for working capital and general corporate purposes. It estimates that existing cash, cash equivalents and marketable securities, together with anticipated net proceeds from this financing, will fund operations into mid‑2029, supporting development of programs including SCY‑770 for autosomal dominant polycystic kidney disease.
SCYNEXIS, Inc. entered into a private placement with institutional and accredited investors to raise approximately $40.0 million in gross proceeds. The company will issue 34,750,000 common shares, 8,750,000 pre-funded warrants, and accompanying common warrants to purchase up to 43,500,000 shares or pre-funded warrants.
Common shares plus warrants are priced at $0.92 per unit, and pre-funded warrant units at $0.9199. Common warrants carry a $1.20 exercise price and become exercisable after stockholder approval of an authorized share increase. If all warrants are exercised for cash, SCYNEXIS could receive up to an additional $52.2 million.
The company plans to use net proceeds for working capital and general corporate purposes. It estimates that existing cash, cash equivalents and marketable securities, together with anticipated net proceeds from this financing, will fund operations into mid‑2029, supporting development of programs including SCY‑770 for autosomal dominant polycystic kidney disease.
SCYNEXIS, Inc. entered into an Asset Purchase Agreement with Poxel SA to acquire Poxel’s direct AMP kinase activator research program, including lead compound PXL-770, now SCY-770, for rare kidney disease ADPKD. SCYNEXIS will make a one-time upfront payment of $8,000,000 within 30 days of the agreement’s effective date and may pay up to $188,000,000 in development and commercial milestone payments tied to clinical progress and annual net sales thresholds.
The deal also includes an exclusive, sublicensable, perpetual worldwide license to related Poxel intellectual property. SCY-770 has been tested in eight clinical trials with a favorable safety profile and is planned to enter a Phase 2 proof-of-concept study in ADPKD in Q4 2026, with an early efficacy readout anticipated in the second half of 2027. SCY-770 holds FDA Orphan Drug Designation, while SCYNEXIS continues to develop its antifungal franchise, including potential BREXAFEMME milestones up to $146 million and ongoing Phase 1 work on SCY-247.
SCYNEXIS, Inc. entered into an Asset Purchase Agreement with Poxel SA to acquire Poxel’s direct AMP kinase activator research program, including lead compound PXL-770, now SCY-770, for rare kidney disease ADPKD. SCYNEXIS will make a one-time upfront payment of $8,000,000 within 30 days of the agreement’s effective date and may pay up to $188,000,000 in development and commercial milestone payments tied to clinical progress and annual net sales thresholds.
The deal also includes an exclusive, sublicensable, perpetual worldwide license to related Poxel intellectual property. SCY-770 has been tested in eight clinical trials with a favorable safety profile and is planned to enter a Phase 2 proof-of-concept study in ADPKD in Q4 2026, with an early efficacy readout anticipated in the second half of 2027. SCY-770 holds FDA Orphan Drug Designation, while SCYNEXIS continues to develop its antifungal franchise, including potential BREXAFEMME milestones up to $146 million and ongoing Phase 1 work on SCY-247.
SCYNEXIS, Inc. entered into an Asset Purchase Agreement with Poxel SA to acquire Poxel’s direct AMP kinase activator research program, including lead compound PXL-770, now SCY-770, for rare kidney disease ADPKD. SCYNEXIS will make a one-time upfront payment of $8,000,000 within 30 days of the agreement’s effective date and may pay up to $188,000,000 in development and commercial milestone payments tied to clinical progress and annual net sales thresholds.
The deal also includes an exclusive, sublicensable, perpetual worldwide license to related Poxel intellectual property. SCY-770 has been tested in eight clinical trials with a favorable safety profile and is planned to enter a Phase 2 proof-of-concept study in ADPKD in Q4 2026, with an early efficacy readout anticipated in the second half of 2027. SCY-770 holds FDA Orphan Drug Designation, while SCYNEXIS continues to develop its antifungal franchise, including potential BREXAFEMME milestones up to $146 million and ongoing Phase 1 work on SCY-247.